Etiology and pathogenesis of the metabolic syndrome;Ätiologie und pathogenese des metabolischen syndroms

Diabetes und Stoffwechsel

Volumn 14, Issue 6, 2005, Pages 333-349

  Julius, Ulrich ^a   Schulze, J ^a   Hanefeld, M ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Dyslipidemia; Insulin resistance; Metabolic syndrome; Type 2 diabetes mellitus; Visceral obesity

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ALCOHOL CONSUMPTION; COMORBIDITY; DYSLIPIDEMIA; FATTY LIVER; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SLEEP APNEA SYNDROME; THROMBOPHILIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33751583974     PISSN: 09420037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Hanefeld M, Leonhardt W: Das metabolische Syndrom. Dt Gesundh Wesen 36 (1981) 545-51
2. Hanefeld M: Das Metabolische Syndrom: Wurzeln, Mythen und Fakten. In: Hanefeld M, Leonhardt W (ed): Das Metabolische Syndrom. Gustav Fischer Verlag, Jena Stuttgart (1996) 15-26
3. World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation Geneva (1999)
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute, 2001 May. 28. Third report of the National Cholesterol Education Program (NCEP). JAMA 285 (2001) 2486-97
5. Alberti K G M M: IDF Consensus on the metabolic syndrome: definition and treatment. First International Congress on "Prediabetes" and the Metabolic Syndrome, Berlin, (2005)
6. Ginsberg H N, Huang L S: The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 7 (2000) 325-331
7. Julius U: influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp Clin Endocrinol Diabetes 111 (2003) 246-250
8. Pietzsch J, Julius U, Kirch C, Fischer S, Hanefeld M: Very low density lipoprotein overproduction is maximally expressed in early insulin resistant states. Ann NY Acad Sci 892 (1999) 319-322
9. McCarty M F: A paradox resolved: the postprandial model of insulin resistance explains why gynoid adiposity appears to be protective. Med Hypotheses 61 (2003) 173-6
10. Boden G: Die Rolle Freier Fettsäuren in der Pathogenese von Insulinresistenz und Typ-II-Diabetes. In: Hanefeld M, Leonhardt W (ed): Das Metabolische Syndrom - ein integriertes Konzept zur Diagnostik und Therapie eines Clusters von Zivilisationskrankheiten. Gustav Fischer Verlag, Jena Stuttgart (1996) 113-117
11. Eckel R H, Grundy S M, Zimmet P Z: The metabolic syndrome. Lancet 365 (2005) 1415-28
12. Björntorp P: Obesity, insulin resistance and diabetes. In: Alberti KGM M, Krall L P (ed): The Diabetes Annual/6. Elsevier Science Publishers (1991) 347-370
13. Bloomgarden Z T: The 1st world congress on the insulin resistance syndrome. Diabetes Care 27 (2004) 602-609
14. Schinner S, Scherbaum W A, Bornstein S R, Barthel A: Molecular mechanisms of insulin resistance. Diabet Med 22 (2005) 674-82
15. Krebs M, Roden M: Nutrient-induced insulin resistance in human skeletal muscle. Curr Med Chem 11 (2004) 901-908
16. Ilanni-Parikka P, Eriksson J G, Lindström J, Hämälä inen H, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Rastas M, Salminen V, Aunola S, Sundvali J, Valle T, Lahtela J, Uusitupa M, Tuomilehto J, on behalf of the Finnish Diabetes Prevention Study Group: Prevalence of the metabolic syndrome and its components - Findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care 27 (2004) 2135-2140
17. Muller-Wieland D, Kotzka J: SREBP-1: gene regulatory key to syndrome X?. Ann N Y Acad Sci 967 (2002) 19-27
18. Brage S, Wedderkopp N, Ekelund U, Franks P W, Wareham N J, Andersen L B, Froberg K: Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in Danish children. Diabetes Care 27 (2004) 2141-48
19. Laaksonen D E, Lakka H M, Salonen J T, Niskanen L K, Rauramaa R, Lakka T A: Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes Care 25 (2002) 1612-18
20. Ekelund U, Brage S, Franks P W, Hennings S, Emms S, Wareham N J: Physical activity energy expenditure predicts progression toward the metabolic syndrome independently of aerobic fitness in middle-aged healthy Caucasians. Diabetes Care 28 (2005) 1195-1200
21. Thanopoulou A C, Karamanos B G, Angelico F V, Assaad-Khalil S H, Barbato A F, Del Ben M P, Djordjevic P B, Dimitrijevic-Sreckovic V S, Gallotti C A, Katsilambros N L, Migdalis I N, Mrabet M M, Petkova M K, Roussi D P, Tenconi M-T P: Dietary fat intake as risk factor for the development of diabetes. Diabetes Care 26 (2003) 302-307
22. Jehn M, Clark J M, Guallar E: Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27 (2004) 2422-8
23. Pankow J S, Jacobs D R, Steinberger J, Moran A, Sinaiko A R: Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance (metabolic) syndrome. Diabetes Care 27 (2004) 775-780
24. Maumus S, Marie B, Siest G, Visvikis-Siest S: A prospective study on the prevalence of metabolic syndrome among healthy french families: two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor-alpha) are revealed in the offspring of parents with metabolic syndrome. Diabetes Care 28 (2005) 675-82
25. Marini M A, Frontoni S, Mineo D, Bracaglia D, Cardellini M, De Nicolais P, Baroni A, D'Alfonso R, Perna M, Lauro D, Federici M, Gambardella S, Lauro R, Sesti G: The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patient. J Clin Endocrinol Metab 88 (2003) 3368-3371
26. Baroni M G, Area M, Sentinelli F, Buzzetti R, Capici F, Lovari S, Vitale M, Romeo S, Di Mario U: The G972R variant of the insulin receptor substrate-1 (IRS-1) gene, body fat distribution and insulin resistance. Diabetologia 44 (2001) 367-372
27. Altshuler D, Hirschhorn J N, Klannemark M, Lindgren C, Vohl M, Nemesh J, Lane C, Schaffner S, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson T, Daly M, Groop L, Lander E: The common PPARgamma Prol2Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26 (2000) 76-80
28. Eriksson J, Lindi V, Uusitupa M, Forsen. TJ, Laakso M, Osmond C, Barker D: The effects of the Pro12Ala polymorphism of the peroxisome prolife-ratror-activated receptor-gamma2 gene on insulin sensitivity and insulin metabolism interact with size at birth. Diabetes 51 (2002) 2321-2324
29. Nestel P J: Metabolic syndrome; multiple candidate genes, multiple environmental factors: multiple syndromes?. Int J Clin Practice 134 (Suppl) (2003) 3-9
30. Carr D, Utzschneider K M, Hull R L, Kodama K, Retzlaff B M, Brunzell J D, Shofer J B, Fish B E, Knopp R H, Kahn S E: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53 (2004) 2087-94
31. Bloomgarden Z T: Dylipidemia and the metabolic syndrome. Diabetes Care 27 (2004) 3009-16
32. Nieves D J, Cnop M, Retzlaff B, Walden C E, Brunzell J D, Knopp R H, Kahn S E: The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to infra-abdominal fat. Diabetes 52 (2003) 172-79
33. Tremblay A J, Despres J P, Piche M E, Nadeau A, Bergeron J, Almeras N, Tremblay A, Lemieux S: Associations between the fatty acid content of triglyceride, visceral adipose tissue accumulation, and components of the insulin resistance syndrome. Metabolism 53 (2004) 310-317
34. Björntorp P: Abdominal obesity and the development of non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 4 (1988) 615-622
35. Janssen I, Katzmarzyk P T, Ross R: Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 79 (2004) 347-349
36. Palaniappan L, Carnethon M R, Wang Y, Hanley A J G, Fortmann S P, Haffner S M, Wagenknecht L: Predictors of the incident metabolic syndrome in adults. Diabetes Care 27 (2004) 788-793
37. Carnethon M R, Loria C M, Hill J O, Sidney S, Savage PJ, Liu K: Risk factores for the metabolic syndrome - The Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care 27 (2004) 2707-15
38. Freiberg M S, Cabral H J, Heeren T C, Vasan R S, Ellison R C: Alcohol consumption and the prevalence of the metabolic syndrome in the U.S. - A cross-sectional analysis of dat from the Third National Health and Nutrition Examination Survey. Diabetes Care 27 (2004) 2954-59
39. Hodge A M, English D R, O'Dea K, Giles G G: Glycemic index and dietary fiber and the risk of type 2 diabetes. Diabetes Care 27 (2004) 2701-6
40. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly D, Haffner S, Isles C, Macfarlane P, Packard C, Cobbe S, Shepherd: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
41. Hu F B, Manson J E, Stampfer M J, Colditz G, Liu S, Solomon C G, Willett W C: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345 (2001) 790-797
42. Laaksonen D E, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T P, Valkonen V P, Salonen R, Salonen J T: Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27 (2004) 1036-41
43. D'Agostino Jr. R B, Hamman R F, Karter A J, Mykkanen L, Wagenknecht L E, Haffner S M: Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 27 (2004) 2234-40
44. Dotevall A, Johansson S, Wilhelmsen L, Rosengren A: Increased levels of triglycerides, BMI and blood pressure and low physical activity increase the risk of diabetes in Swedish women. A prospective 18-year follow-up of the BEDA study. Diabet Med 21 (2004) 615-22
45. Lorenzo C, Okoloise M, Williams K, Stern M P, Haffner S M: The metabolic syndrome as predictor of type 2 diabetes - The San Antonio Heart Study. Diabetes Care 26 (2003) 3153-59
46. Stern M P, Williams K, González-Villalpando C, Hunt K J, Haffner S M: Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?. Diabetes Care 27 (2004) 2676-81
47. Wyszynski D F, Waterworth D M, Barter P J, Cohen J, Kesaniemi Y A, Mahley R W, McPherson R, Waeber G, Bersot T P, Sharma S S, Nolan V, Middleton L T, Sundseth S S, Farrer L A, Mooser V, Grundy S M: Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol 95 (2005) 194-8
48. Pietzsch J, Julius U, Hanefeld M: Metabolic basis of low high density lipoprotein in subjects with impaired glucose tolerance. Ann NY Acad Sci 892 (1999) 323-326
49. Julius U, Kirschner E, Pietzsch J: Intravasaler Lipidtransfer bei gestörter Glukosetoleranz (IGT): Beitrag zur Rolle des Cholesteroiester- Transferproteins (CETP). In: Heinle H, Schulte H, Hahmann H (ed): Besondere Aspekte der cerebrovaskulären und peripheren Arteriosklerose. Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen (2004) 50-54
50. Holvoet P, Kritchevsky S B, Tracy R P, Mertens A, Rubin S M, Butler J, Goodpaster B, Harris T B: The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 53 (2004) 1068-1073
51. Holvoet P: Oxidized LDL and coronary heart disease. Acta Cardiol 59 (2004) 479-84
52. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch H J, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39 (1996) 1577-83
53. Alexander C M, Landsman P B, Teutsch S M, Haffner S M: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). Diabetes 52 (2003) 1210-14
54. Malik S, Wong N D, Franklin S, Pio J, Fairchild C, Chen R: Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 28 (2005) 690-3
55. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Cacciatori V, Santi L, Targher G, Bonadonna R, Muggeo M: HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Diabetes Care 25 (2002) 1135-1141
56. Rewers M, Zaccaro D, D'Agostino R, Haffner S, Saad M F, Selby J V, Bergman R, Savage P, for the Insulin Resistance Atherosclerosis Study Investigators: Insulin sensitivity, insulinemia, and coronary artery disease - The Insulin Resistance Atherosclerosis Study. Diabetes Care 27 (2004) 781-787
57. Ninomiya J K, L'Italien G, Criqui M, Whyte J, Gamst A, Chen R: Association of the Metabolic Syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109 (2004) 42-46
58. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Gemma L, Santi L, Bonadonna R C, Muggeo M: The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 21 (2004) 52-8
59. Solymoss B C, Bourassa M G, Campeau L, Sniderman A, Marcil M, Lesperance J, Levesque S, Varga S: Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 93 (2004) 159-64.
60. Kip K E, Marroquin O C, Kelley D E, Johnson B D, Kelsey S F, Shaw L J, Rogers W J, Reis S E: Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report rom the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 109 (2004) 706-13
61. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Rissen M, Taskinen M R, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-9
62. 1c level. Diabetes Care 23 (2000) 1830-4.
63. Temelkova-Kurktschiev T, Koehler C, Henkel I, Hanefeld M: Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes. Cardiorasc Res 56 (2002) 277-83
64. McNeill A M, Rosamond W D, Girman C J, Golden S H, Schmidt M I, East H E, Ballantyne C M, Heiss G: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 28 (2005) 385-390
65. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, Cerai S P, Pagano G, Cavallo-Perin P: Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes - The Nasale Monferrato Study. Diabetes Care 27 (2004) 2689-94
66. Ford ES: The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 168 (2003) 351-8
67. Chen J, Wildman R P, Hamm L L, Muntner P, Reynolds K, Whelton P K, He J: Association between inflammation and insulin resistance in U.S. nondiabetic adults - Results from the Third National Health and Nutrition Examination Survey. Diabetes Care 27 (2004) 2960-68
68. Duncan B B, Schmidt M I, Pankow J S, Ballanryne C, Couper D, Vigo A, Hoogeveen R, Folsom A, Heiss G, Atherosclerosis Risk in Communities Study: Atherosclerosis Risk in Communities Study. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52 (2003) 1799-1805
69. Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel K, Kochler C, Jaross W, Hanefeld M: Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 51 (2002) 743-9.
70. Ridker P M, Hennekens C H, Buring J E. Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-42
71. Hu F B, Meigs J B, Li T Y, Ritai N, Manson J E: Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53 (2004) 693-700
72. King D E, Mainous A G 3, Thomas A, Pearson W: C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 26 (2003) 1535-2539
73. Kaushal K, Heald A H, Siddals K W, Sandhu M S, Dunger D B, Gibson J M, Wareham N J: The impact of abnormalities in IGF and inflammatory systems on rhe metabolic syndrome. Diabetes Care 27 (2004) 2682-88
74. Chandran M, Phillips S A, Ciaraldi T, Henry R R: Adiponectin: More than just another fat cell hormone?. Diabetes Care 26 (2003) 2442-2450
75. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagarerani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y: Diet-induced insulin resistance in mice lacking adiponectin ACRP30. Nat Med 8 (2002) 731-737
76. Cnop M, Havel PJ, Utzscbneider K M, Carr E B, Sinha M K, Boyko E J, Retzlaff B M, Knopp R H Brunzell J D, Kahn S E: Relationship of adiponectir to body fat distribution, insulin sensitivity and plasm; hpoproteins: evidence for independent roles of age and sex. Diabetologia 46 (2003) 459-469
77. Abbasi F, Chu J W, Lamendola C, McLaughlin T, Hayden J, Reaven G M, Reaven P D: Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes 53 (2004) 585-590
78. Sierksma A, Patel H, Ouchi N, Kihara S, Funahashi T, Heine R J, Grobbee D E, Kluft C, Hendrik H F J: Effect of moderate alcohol consumption 01 adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care 27 (2004) 184-189
79. Sonnenberg G E, Krakower G R, Kissebah A H A novel pathway to rhe manifestations of metabolic syndrome. Obes Res 12 (2004) 180-186
80. Alvarez G E, Beske S D, Ballard T P, Davy K P: Sympathetic neural activation in visceral obesit: Circulation 106 (2002) 2533-2536
81. Philipp T: Metabolisches Syndrom und Hypertonie. In: Hanefeld M. Leonhardt W (ed): Das Me tabolische Syndrom - ein integriertes Konzept zu Diagnostik und Therapie eines Clusters von Zivilisationskrankheiten. Gustav Fischer Verlag, Jena Stuttgart (1996) 70-75
82. Brunner E J, Hemingway H, Walker B R, Page M, Clarke P, Juneja M, Shipley M, Kumari M, Andrew R, Seckl J, Papadopoulos A, Checkley S, Rumley A, Lowe G, Stansfeld S, Marmot M: Adrenocortical, autonomic and inflammatory causes of the metabolic syndrome. Circulation 106 (2002) 2659-2665
83. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H: Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity: European Group for the Study of Insulin Resistance (EGIR). Hypertension 30 (1997) 1144-1149
84. DeFronzo R A, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 173-194
85. Facchini F S, DoNascimento C, Reaven G M, Yip J W, Ni X P, Humphreys M H: Blood pressure, sodium intake, insulin resistance, and urinary nitrate excretion. Hypertension 33 (1999) 1008-1012
86. Engeli S, Schling P, Gorzelniak K, Boschmann M, anke J, Ailhaud G, Teboul M, Massiera F, Sharma A M: The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol 35 (2003) 807-25
87. Sharma A M: Is there a rationale for angiotensin blockade in the management of obesity hypertension?. Hypertension 44 (2004) 12-9
88. Ehrhart-Bornstein M, Arakelyan K, Krug A W, Scherbaum W A, Bornstein S R: Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 30 (2004) 865-70
89. Dieterle P, Bottermann P, Schwarz K: Bedeutung der Hypertonie in der Pathogenese des Diabetes mellitus. Verh Dtsch Ges Inn Med 74 (1968) 434-7
90. Anand S S, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P, Yusuf S, Study of Health Assessment and Risk in Ethnic Groups, Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators: Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108 (2003) 420-425
91. Al Suwaidi J, Higano S, Holmes D J, Lennon R, Lerman A: Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 37 (2001) 1523-1528
92. Steinberg H O, Chaker H, Learning R, Johnson A, Brechtel G, Baron A D: Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest 97 (1996) 2601-2610
93. Vehkavaara S, Seppälä-Lindroos A, Wesrerbacka J, Groop P-H, Yki-Järvinen H: In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care 22 (1999) 2055-2060
94. Sanyal A J, Campbell-Sargent C, Mirshahi F, Rizzo W B, Contos M J, Sterling R K, Luketic V A, Shiffman M L, Clore J N: Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
95. Björntorp P: Neuroendokrine Anomalien beim Metabolischen Syndrom. In: Hanefeld M, Leonhardt W (ed): Das Metabolische Syndrom - ein integriertes Konzept zur Diagnostik und Therapie eines Clusters von Zivilisationskrankheiten. Gustav Fischer Verlag Jena Stuttgart (1996) 53-61
96. Andrew R, Westerbacka J, Wahren J, Yki-Järvinen H, Walker B R: The contribution of viscera adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 54 (2005) 1364-1370
97. Muller M, Grobbee D E, den Tonkelaar I, Lam berts S W, van der Schouw Y T: Endogenous sex hormones and metabolic syndrome in aging men. Clin Endocrinol Metab 90 (2005) 2618-23
98. Laaksonen D E, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T-P, Valkonen V-P, Salonen J T: The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 90 (2005) 712-9
99. Mor E, Zograbyan A, Saadat P, Bayrak A, Tourgeman D E, Zhang C, Stanczyk F Z, Paulson RJ: The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis. Am J Obstet Gynecol 190 (2004) 1654-60
100. Laaksonen D E, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T-P, Salonen R, Rauramaa R, Salonen J T: Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 49 (2003) 601-8
101. Tsai E C, Matsumoto A M, Fujimoto W Y, Boyko E J: Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 27 (2004) 861-8
102. Abate N, Haffner S M, Garg A, Peshock R M, Grundy S M: Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 87 (2002) 4522-7
103. Lee C C, Kasa-Vubu J Z, Supiano M A: Androgenicity and obesity are independently associated with insulin sensitivity in postmenopausal women. Metabolism 53 (2004) 507-12
104. Kalish G M, Barrert-Connor E, Laughlin G A, Gulanski B I: Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab 88 (2003) 1646-52
105. Golden S H, Ding J, Szklo M, Schmidt M I, Duncan B B, Dobs A: Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study. Am J Epidemiol 160 (2004) 540-8
106. Apridonidze T, Essah P A, Iuorno M J, Nestler J E: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 1929-35
107. Buffington C K, Kitabchi A E: Evidence for a defect in insulin metabolism in hyperandrogenic women with polycystic ovarian syndrome. Metabolism 43 (1994) 1367-72.
108. Schernthaner G: Gestörte Hàmostase bei Diabetes mellitus und Metabolischem Syndrom: Einfluβ faktoren und potentielle Therapieinterventionen. In: Hanefeld M, Leonhardt W (ed): Das Metabolische Syndrom - ein integriertes Konzept zur Diagnostik und Therapie eines Clusters von Zivilisationskrankheiten. Gustav Fischer Verlag, Jena Stuttgart (1996) 138-161
109. Wannamethee S G, Lowe GDO, Shaper A G, Rumlev A, Lennon L, Whincup P H: The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older nondiabetic men. Atherosclerosis 181 (2005) 101-8
110. Godsland I F, Crook D, Proudler A J, Stevenson J C: Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Endocrinol Metab 90 (2005) 190-7
111. Tarkun I, Canturk Z, Arslan B C, Turernen E, Tarkun P: The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr. J 51 (2004) 467-72
112. Mavri A, Alessi MC, Julian-Vague I: Hypofiberinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. J Intern Med 255 (2004) 448-56.
113. Coughlin S R, Mawdsley L, Mugarza J A, Calverley P M, Wilding J P: Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 25 (2004) 735-741
114. Matsubara M, Chiba H, Maruoka S, Katayose S: Elevated serum leptin concentrations in women with hyperuricemia. J Atheroscler Thromb 9 (2002) 28-34
115. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G: Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur J Clin Invest 31 (2001) 318-21
116. Wannamethee S G, Shaper A G, Durrington P N, Perry I J: Hypertension, serum insulin, obesity and the metabolic syndrome. J Hum Hypertens 12 (1998) 735-41
117. Clausen J O, Borch-Johnsen K, Ibsen H, Pedersen O: Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians. Eur J Endocrinol 138 (1998) 63-9.
118. Bonora E, Targher G, Zenere M B, Saggiani F, Cacciatori V, Tosi F, Travia D, Zenti M G, Branzi P, Santi L, Muggeo M: Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord 20 (1996) 975-80
119. Schmidt M I, Watson R L, Duncan B B, Metcalf P, Brancati F L, Sharrett A R, Davis C E, Heiss G: Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism 45 (1996) 699-706.
120. Vuorinen-Markkola H, Yki-Jarvinen H: Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 78 (1994) 25-9
121. Zavaroni I, Mazza S, Fantuzzi M, Dall'Aglio E, Bonora E, Delsignore R, Passeri M, Reaven G M: Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemia. J Intern Med 234 (1993) 25-30
122. Langlois M, De Bacquer D, Duprez D, De Buyzere M, Delanghe J, Blaton V: Serum uric acid in hypertensive patients with and without peripheral arterial disease. Atherosclerosis 168 (2003) 163-8
123. Denzer C, Muche R, Mayer H, Heinze E, Debatin K M, Wabitsch M: Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome. J Pediatr Endocrinol Metab 16 (2003) 1225-32
124. Carnethon M R, Fortmann S P, Palaniappan L, Duncan B B, Schmidt M I, Chambless L E: Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 158 (2003) 1058-67
125. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka R, Zhu S, Toyoshima H: The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 27 (2003) 443-9
126. Fruehwald-Schultes B, Peters A, Kern W, Beyer J, Pfutzner A: Serum leptin is associated with serum uric acid concentrations in humans. Metabolism 48 (1999) 677-80.
127. Facchini F, Chen Y D, Hollenbeck C B, Reaven G M: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266 (1991) 3008-11
128. Alexander C M: The coming of age of the metabolic syndrome. Diabetes Care 26 (2003) 3180-81
129. Hanefeld M, Köhler C: Das Metabolische Syndrom im Wandel: Historische Perspektive und epidemiologische Dimension. In: Hanefeld M, Julius U (ed): Das Metabolische Syndrom 2000 - eine postprandiale Krankheit?. Urban & Fischer, München Jena (2001) 15-24